MEDIFASTvsProcter & Gamble

MED and PG stock compared: price, dividend, valuation and results, from SEC filings.

PG

The Procter & Gamble Company

$169.80

Value $395B

+1.05%
PG's page

MEDIFAST (MED) has a market value of $143M and Procter & Gamble (PG) $395B. Over the last year, with dividends, MED moved +11.5% and PG +18.0%. Dividend yield: MED 0.12%, PG 2.55%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MED$143M

    PG$395B

    PG is 2,769 times MED

  • Revenue, 12 months

    MED$300M

    PG$87.9B

    PG is 293 times MED

  • Net income, 12 months

    MED-$41M

    PG$16.0B

  • Operating margin

    MED-11.6%

    PG22.6%

    34.2 points apart

  • ROIC

    MED-13.9%

    PG17.3%

    31.2 points apart

  • P/E

    MED–

    PG25.1

  • Dividend yield

    MED0.1%

    PG2.6%

    2.5 points apart

  • 5-year return

    MED-93.6%

    PG+31.8%

    125.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MED-93.6%

PG+31.8%

05010020222023202420252026
Returns by period
PeriodMEDWith dividendsPGWith dividends
1 year since November 12, 2025+11.5%Price +11.5%+18.0%Price +14.7%
3 years since November 13, 2023-79.1%-40.7% a yearPrice -79.1%+20.5%+6.4% a yearPrice +11.4%
5 years since November 12, 2021-93.6%-42.4% a yearPrice -94.3%+31.8%+5.7% a yearPrice +15.9%
10 years since November 15, 2016-57.7%-8.2% a yearPrice -66.9%+166.5%+10.3% a yearPrice +103.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MEDMEDIFASTPGProcter & Gamble

Valuation

MEDPG
Valuation
Price$12.97$169.80
Market value$143M$395B
Enterprise value (EV)–$418B
P/E–25.1
P/E, 5-year median12.124.8
P/B0.87.2
EV/EBIT–21.1
Free cash flow yield–3.9%

Results and growth

MEDPG
Results and growth
Revenue, 12 months$300M$87.9B
Net income, 12 months-$41M$16.0B
Free cash flow, 12 months-$3.9M$15.3B
Earnings per share, 12 months-$3.69$6.64
Revenue growth, year on year-36.0%3.3%
Revenue growth a year, past-16.2%over 5 years+2.7%over 5 years
EPS growth a year, past–+3.8%over 5 years

Margins and returns on capital

MEDPG
Margins and returns on capital
Gross margin69.2%49.8%
Operating margin-11.6%22.6%
Net margin-13.6%18.2%
ROIC-13.9%17.3%
ROE-20.7%29.5%

Balance sheet

MEDPG
Balance sheet
Cash$172M$15.4B
Total debt$21M$38.9B
Net debt / EBITDA–1.0
Interest cover–22.0×

Dividends and buybacks

MEDPG
Dividends and buybacks
Dividend yield0.1%2.6%
Dividend per share, 12 months$0.02$4.32
Dividend growth a year, past–+5.6%over 5 years
Buyback yield–1.3%
Shareholder yield0.1%3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MED or PG

Didn't find what you were looking for?

Ask us
Which is bigger, MEDIFAST or Procter & Gamble?

By market value, Procter & Gamble ($395B) is about 2,768.6 times MEDIFAST ($143M), at today's prices.

How did MED and PG stock do over the last 10 years?

Since November 15, 2016, MED's price moved -66.9% and PG's +103.1%. With dividends: MED -57.7% (-8.2% a year), PG +166.5% (+10.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, MED or PG?

The dividend yield at today's price is 0.12% for MEDIFAST and 2.55% for Procter & Gamble. Over the last twelve months they paid $0.02 and $4.32 per share.

Which has the higher profit margins, MEDIFAST or Procter & Gamble?

Over the last twelve months, the net margin was -13.6% for MEDIFAST and 18.2% for Procter & Gamble, and the operating margin -11.6% and 22.6%. Revenue was $300M and $87.9B.

Which is the better investment, MEDIFAST or Procter & Gamble?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.